When Desmond Pedro discovered a strange hardness under his ribcage, he was just 30 and preparing for a fresh start on a government skills course. Little did he know that he would soon die of liver cancer caused by undetected hepatitis B. Sue Segar spent time with his family and spoke to experts to uncover how this overlooked virus continues to claim lives — and what can be done to stop it.
2023 was a busy year for healthcare in South Africa. We saw several promising policy developments, landmark court cases, important pieces of legislation, and some changes in leadership. Yet, take a step back and at facility level little seems to have changed. Shortages of healthcare workers persist, corruption is still rife, budgets tight, and our health governance crisis remains as acute as ever. Marcus Low looks back at the year in health in fewer than 1 000 words.
Almost a decade after they were first proven to be safe and highly effective, game-changing medicines to cure hepatitis C are finally becoming more widely available in South Africa. But not all the regulatory and other challenges behind the delay have yet been overcome and, as a result, access remains relatively limited for now. Catherine Tomlinson reports.
The head of the South African arm of a key COVID-19 vaccine clinical trial is “full of pride” for the teams’ part in the research which has shown the vaccine candidate to be more than 90% effective according to early findings released this week. It however remains unclear whether the vaccine will be available in South Africa once registered. Adele Baleta reports.
Over the last decade the treatment of hepatitis C, a virus that can infect and damage the liver, has been revolutionised by a new class of medicines called direct acting antivirals. Catherine Tomlinson investigates the regulatory obstacles that are limiting access to these breakthrough medicines in South Africa.
A new class of medicines called direct- acting antivirals have revolutionised the treatment of hepatitis C, but access in South Africa remains limited.
